Fang Wang

Dr. Fang Wang

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2022 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
FWFang Wang
Fang Wang
YNYuequn Niu
Yuequn Niu
KCKelie Chen
Kelie Chen
XYXiaoyu Yuan
Xiaoyu Yuan
YQYuheng Qin
Yuheng Qin
DXDajing Xia
Dajing Xia
Ovarian cancer is one of the most common gynecologic malignancies with a highly immunosuppressive tumor microenvironment (TME) and poor prognosis. Circular RNA (circRNA) is a type of noncoding RNA with high stability, which has been shown to play an important role in biological processes and TME reprogramming in a variety of tumors. The biological function of a novel circRNA, circATP2B4, in epithelial ovarian cancer (EOC) was detected and evaluated. Transmission electron microscopy, differential ultracentrifugation and qRT-PCR were used to verify the existence of extracellular vesicles (EV)-packaged circATP2B4. Macrophage uptake of circATP2B4 was determined by EVs tracing. Dual luciferase reporter, FISH, Western blotting, and flow cytometry assays were used to investigate the interactions between circATP2B4 and miR-532-3p as well as sterol regulatory element-binding factor 1 (SREBF1) expression in macrophages. CircATP2B4 was upregulated in EOC tissues and positively correlated with ovarian cancer progression. Functionally, circATP2B4 promoted carcinogenic progression and metastasis of EOC both in vitro and in vivo. Mechanistically, EV-packaged circATP2B4 in EOC could be transmitted to infiltrated macrophages and acted as competing endogenous RNA of miR-532-3p to relieve the repressive effect of miR-532-3p on its target SREBF1. Furthermore, circATP2B4 induced macrophage M2 polarization by regulating the miR-532-3p/SREBF1/PI3Kα/AKT axis, thereby leading to immunosuppression and ovarian cancer metastasis. Collectively, these data indicate that circATP2B4-containing EVs generated by EOC cells promoted M2 macrophages polarization and malignant behaviors of EOC cells. Thus, targeting EVs-packaged circATP2B4 may provide a potential diagnosis and treatment strategy for ovarian cancer.

31 December 2024 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
FWFang Wang
Fang Wang
CYChen Yang
Chen Yang
FZFang Zheng
Fang Zheng
YYYang Yan
Yang Yan
GLGuifang Li
Guifang Li
MYMao Yong
Mao Yong
Colorectal cancer (CRC) is characterized by poor responsiveness to immune evasion and immunotherapy. RNA 7-methylguanine (m7G) modification plays a key role in tumorigenesis. However, the mechanisms by which m7G-modified RNA metabolism affects tumor progression are not fully understood, nor is the contribution of m7G-modified RNA to the CRC immune microenvironment. The expression levels of Methyltransferase-like 1 (METTL1) and m7G in human tissues were determined. In this study, the effect of METTL1 on RNA m7G levels was evaluated, the effect of METTL1 on PKM mRNA modification was confirmed, the expression level of the PKM2 protein was detected, and the mechanism involved RT‒qPCR, Western blot, RNA stability analysis and RIP analysis. Lactate and H3K9 lactylation (H3K9la) induced by METTL1/PKM2 were analyzed via the extracellular acidification rate (ECAR) and lactic acid assays. Cut&Run was used to detect METTL1/PKM2-induced CD155 (PVR) transcription. In addition, METTL1 knockout mice were studied in vivo with CD155 blockers. We demonstrated that m7G RNA METTL1 enhances PKM2 expression by acting on PKM mRNA, leading to tumor progression and increased glycolysis. Specifically, METTL1 mediates m7G methylation of PKM mRNA and enhances the expression of its encoded PKM2, which in turn enhances glycolysis, promotes H3K9la, and activates METTL1 transcription, creating a positive feedback loop. Moreover, increased PKM2 dimer expression and nuclear translocation activated CD155 expression and induced CRC immune evasion. Our findings reveal a general mechanism by which METTL1/PKM2/H3K9la signaling regulates RNA metabolism and highlight METTL1 targeting as a potential strategy for CRC immunotherapy.

1 January 2025 in International Journal of Biological Sciences
Verified
Journal Article
Open access
PDF file
FWFang Wang
Fang Wang
QWQian Wang
Qian Wang
YWYongfeng Wu
Yongfeng Wu
ZHZebo Huang
Zebo Huang
XZXincao Zhong
Xincao Zhong
MYMao Yong
Mao Yong
The effect of immunotherapy for colorectal cancer (CRC) is limited due to anti-tumor immunosuppression. Circular RNAs (circRNAs) are also associated with tumor immunity. The aim of this study was to clarify the regulatory relationship between circRNA and anti-tumor immunosuppression in CRC. CircRNAs associated with CRC were identified using bioinformatic analysis and subsequently confirmed in clinical samples using qRT-PCR and in situ hybridization. The expression, clinical relevance, functional significance and clinical properties of circMVP in CRC specimens and cells were evaluated in vitro and in vivo. RNA pull-down, single-cell RNA sequencing, EMSA, RNA immunoprecipitation, chromatin immunoprecipitation, and polysome profiling assay were performed to confirm the underlying mechanism of circRNA. CircMVP (hsa_circ_0000688) expression was increased in CRC and correlated with poor prognosis in CRC patients. Increased circMVP expression activates proliferation, invasion, and tumorigenesis of CRC. In addition, we found that circMVP, by interacting with METTL3, stabilizes its expression in the nucleus and significantly enhances its mediated N6-methyladenosine (m6A) modification. Specifically, circMVP/METTL3 promoted the expression of β-catenin by directly acting on CTNNB1 mRNA. CircMVP/METTL3 further enhanced the expression of B7-H3 through the β-catenin signaling pathway. Notably, inhibition of circMVP expression significantly improved the efficacy of anti-B7-H3 immunotherapy in in vivo and in vitro models. CircMVP mediated CTNNB1 m6A modification by promoting METTL3 activation and inhibited B7-H3-dependent anti-tumor immune response in CRC. In conclusion, circMVP may be a predictor of CRC immune evasion and a potential therapeutic target.

4 September 2025 in Ecotoxicology and Environmental Safety
Verified
Journal Article
Open access
YYYang Yan
Yang Yan
JLJiaxuan Li
Jiaxuan Li
HXHejia Xu
Hejia Xu
CYChen Yang
Chen Yang
GLGuifang Li
Guifang Li
MYMao Yong
Mao Yong
Colorectal cancer (CRC) is characterised by microbial dysbiosis. Trimethylamine (TMA) and trimethylamine-N-oxide (TMAO) are gut microbiota-derived metabolites produced from dietary precursors that are implicated in CRC progression. However, the underlying mechanisms by which TMA or TMAO affect CRC progression remain largely unexplored. Therefore, in this study, we aimed to investigate the effects of TMA and TMAO on CRC progression. The methods used included real-time PCR, western blotting, cell viability and migration assays, apoptosis analysis, single-cell RNA sequencing, and tumor xenograft models. We demonstrated that exposure to both TMA and TMAO promoted CRC cell proliferation. Notably, treatment with 1 μM TMA and 100 μM TMAO had the greatest effect on enhancing CRC cell invasion and migration, while also reducing apoptosis. Mechanistically, TMA and TMAO modulated the expression of sterol regulatory element-binding factor 1 (SREBF1) and activated the phosphoinositide 3-kinase (PI3K)/ protein kinase B (AKT) signalling pathway, thereby contributing to CRC progression. In mouse subcutaneous tumour experiments, a high-TMAO diet accelerated CRC progression, leading to significantly larger tumour volumes than those in the control group. Collectively, these findings suggest a potential correlation between elevated serum TMAO levels and CRC progression. Notably, we provide the first evidence that TMA and TMAO promote CRC cell proliferation via activation of the PI3K/AKT signalling pathway, with SREBF1 serving as a key mediator of TMA- and TMAO-induced CRC proliferation. Reducing TMA and TMAO intake through dietary intervention and the use of SREBF1 inhibitors may delay CRC progression, offering considerable clinical potential for therapeutic applications.

26 November 2025
Verified
Other
Open access
FWFang Wang
Fang Wang
YNYuequn Niu
Yuequn Niu
KCKelie Chen
Kelie Chen
XYXiaoyu Yuan
Xiaoyu Yuan
YQYuheng Qin
Yuheng Qin
DXDajing Xia
Dajing Xia
Ovarian cancer is one of the most common gynecologic malignancies with a highly immunosuppressive tumor microenvironment (TME) and poor prognosis. Circular RNA (circRNA) is a type of noncoding RNA with high stability, which has been shown to play an important role in biological processes and TME reprogramming in a variety of tumors. The biological function of a novel circRNA, circATP2B4, in epithelial ovarian cancer (EOC) was detected and evaluated. Transmission electron microscopy, differential ultracentrifugation and qRT-PCR were used to verify the existence of extracellular vesicles (EV)-packaged circATP2B4. Macrophage uptake of circATP2B4 was determined by EVs tracing. Dual luciferase reporter, FISH, Western blotting, and flow cytometry assays were used to investigate the interactions between circATP2B4 and miR-532-3p as well as sterol regulatory element-binding factor 1 (SREBF1) expression in macrophages. CircATP2B4 was upregulated in EOC tissues and positively correlated with ovarian cancer progression. Functionally, circATP2B4 promoted carcinogenic progression and metastasis of EOC both in vitro and in vivo. Mechanistically, EV-packaged circATP2B4 in EOC could be transmitted to infiltrated macrophages and acted as competing endogenous RNA of miR-532-3p to relieve the repressive effect of miR-532-3p on its target SREBF1. Furthermore, circATP2B4 induced macrophage M2 polarization by regulating the miR-532-3p/SREBF1/PI3Kα/AKT axis, thereby leading to immunosuppression and ovarian cancer metastasis. Collectively, these data indicate that circATP2B4-containing EVs generated by EOC cells promoted M2 macrophages polarization and malignant behaviors of EOC cells. Thus, targeting EVs-packaged circATP2B4 may provide a potential diagnosis and treatment strategy for ovarian cancer.